1
|
Beishon L, Haunton VJ, Panerai RB. Antihypertensives in dementia: Good or bad for the brain? J Cereb Blood Flow Metab 2023; 43:1800-1802. [PMID: 36284494 PMCID: PMC10581243 DOI: 10.1177/0271678x221133473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/21/2022] [Revised: 07/19/2022] [Accepted: 07/29/2022] [Indexed: 11/15/2022]
Abstract
Hypertension is associated with both ageing and dementia. Despite this, optimal blood pressure targets in dementia remain unclear. Both high and low blood pressure are associated with poorer cognition. Changes in vascular physiology in dementia may increase the vulnerability of the brain to hypoperfusion associated with antihypertensives. We discuss the potential risks of antihypertensives in the context of altered cerebral haemodynamics, and evidence from antihypertensive trials in dementia. We suggest that individualised blood pressure targets should be the focus for antihypertensive therapy in dementia, rather than strict control to uniform targets extrapolated from trials in cognitively healthy individuals.
Collapse
Affiliation(s)
- Lucy Beishon
- Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
- NIHR Leicester Biomedical Research Centre, British Heart Foundation Cardiovascular Research Centre, Glenfield Hospital, Leicester, UK
| | | | - Ronney B Panerai
- Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
- NIHR Leicester Biomedical Research Centre, British Heart Foundation Cardiovascular Research Centre, Glenfield Hospital, Leicester, UK
| |
Collapse
|
2
|
Bogaerts JMK, Warmerdam LA, Achterberg WP, Gussekloo J, Poortvliet RKE. Proxy Decision-Making for Clinical Research in Nursing Home Residents With Dementia: A Qualitative Analysis. J Am Med Dir Assoc 2023; 24:541-547.e2. [PMID: 36924797 DOI: 10.1016/j.jamda.2023.02.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2022] [Revised: 02/16/2023] [Accepted: 02/16/2023] [Indexed: 03/14/2023]
Abstract
OBJECTIVES The benefit-risk ratio of many interventions remains unclear in older adults with dementia. Efforts for more representative trial inclusion are made; however, recruiting and particularly gaining informed consent remains complex. For research participation, dementia compels the designation of a legal guardian (LG) to give proxy consent. To advance future trial development, we aimed to provide more insights into the factors that affect the proxy decision-making process in dementia research. DESIGN A qualitative analysis of semi-structured interviews about proxy decision-making on participation in dementia research. SETTING AND PARTICIPANTS LGs of nursing home residents that gave (n = 19) and refrained from giving (n = 18) proxy consent for a clinical trial (the ∗∗∗BLINDED∗∗∗ study) in the Netherlands. METHODS Verbatim transcripts were thematically analyzed by using a preliminary deductive framework with room for induction of additional emerging themes, being an overall abductive approach. Based on that theme list, related factors of the decision-making process were grouped into overarching levels and merged into a step-by-step process. RESULTS When discussing proxy decision-making on the participation of an older adult with dementia in a clinical trial, LGs described interconnected factors on the level of the study and patient. Past experiences and attitudes of the LG influenced the weighing of these study- and patient-related factors, leading to a preliminary decision. Other proxies and treating health care professionals (HCPs) were named as important other stakeholders of the decision-making process. CONCLUSIONS AND IMPLICATIONS When giving proxy consent for research participation, LGs weigh study- and patient-related factors, leading to an initial benefit-risk evaluation. This weighing process is influenced by LG-related factors and can be modulated by other proxies or treating HCPs, leading to a definitive decision. Although insights into these underlying mechanisms could facilitate the proxy decision-making process for both LGs and researchers, treating HCPs could act as an independent party.
Collapse
Affiliation(s)
- Jonathan M K Bogaerts
- Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, the Netherlands.
| | - Laurie A Warmerdam
- Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, the Netherlands
| | - Wilco P Achterberg
- Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, the Netherlands; University Network for the Care sector South Holland, Leiden University Medical Center, Leiden, the Netherlands
| | - Jacobijn Gussekloo
- Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, the Netherlands; Department of Internal Medicine, Section Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands
| | - Rosalinde K E Poortvliet
- Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, the Netherlands; University Network for the Care sector South Holland, Leiden University Medical Center, Leiden, the Netherlands
| |
Collapse
|
3
|
Koide M, Harraz OF, Dabertrand F, Longden TA, Ferris HR, Wellman GC, Hill-Eubanks DC, Greenstein AS, Nelson MT. Differential restoration of functional hyperemia by antihypertensive drug classes in hypertension-related cerebral small vessel disease. J Clin Invest 2021; 131:e149029. [PMID: 34351870 PMCID: PMC8439604 DOI: 10.1172/jci149029] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2021] [Accepted: 07/28/2021] [Indexed: 02/05/2023] Open
Abstract
Dementia resulting from small vessel diseases (SVDs) of the brain is an emerging epidemic for which there is no treatment. Hypertension is the major risk factor for SVDs, but how hypertension damages the brain microcirculation is unclear. Here, we show that chronic hypertension in a mouse model progressively disrupts on-demand delivery of blood to metabolically active areas of the brain (functional hyperemia) through diminished activity of the capillary endothelial cell inward-rectifier potassium channel, Kir2.1. Despite similar efficacy in reducing blood pressure, amlodipine, a voltage-dependent calcium-channel blocker, prevented hypertension-related damage to functional hyperemia whereas losartan, an angiotensin II type 1 receptor blocker, did not. We attribute this drug class effect to losartan-induced aldosterone breakthrough, a phenomenon triggered by pharmacological interruption of the renin-angiotensin pathway leading to elevated plasma aldosterone levels. This hypothesis is supported by the finding that combining losartan with the aldosterone receptor antagonist eplerenone prevented the hypertension-related decline in functional hyperemia. Collectively, these data suggest Kir2.1 as a possible therapeutic target in vascular dementia and indicate that concurrent mineralocorticoid aldosterone receptor blockade may aid in protecting against late-life cognitive decline in hypertensive patients treated with angiotensin II type 1 receptor blockers.
Collapse
Affiliation(s)
- Masayo Koide
- Department of Pharmacology, Larner College of Medicine, and,Vermont Center for Cardiovascular and Brain Health, University of Vermont, Burlington, Vermont, USA
| | - Osama F. Harraz
- Department of Pharmacology, Larner College of Medicine, and,Vermont Center for Cardiovascular and Brain Health, University of Vermont, Burlington, Vermont, USA
| | - Fabrice Dabertrand
- Department of Pharmacology, Larner College of Medicine, and,Department of Anesthesiology and,Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
| | - Thomas A. Longden
- Department of Pharmacology, Larner College of Medicine, and,Department of Physiology, University of Maryland School of Medicine, Baltimore, Maryland, USA
| | | | | | | | - Adam S. Greenstein
- Department of Pharmacology, Larner College of Medicine, and,Vermont Center for Cardiovascular and Brain Health, University of Vermont, Burlington, Vermont, USA.,Division of Cardiovascular Sciences, School of Medical Sciences and,Geoffrey Jefferson Brain Research Centre, The Manchester Academic Health Science Centre, Northern Care Alliance NHS Group, University of Manchester, Manchester, United Kingdom
| | - Mark T. Nelson
- Department of Pharmacology, Larner College of Medicine, and,Vermont Center for Cardiovascular and Brain Health, University of Vermont, Burlington, Vermont, USA.,Division of Cardiovascular Sciences, School of Medical Sciences and,Geoffrey Jefferson Brain Research Centre, The Manchester Academic Health Science Centre, Northern Care Alliance NHS Group, University of Manchester, Manchester, United Kingdom
| |
Collapse
|
4
|
Flo-Groeneboom E, Elvegaard T, Gulla C, Husebo BS. The longitudinal association between the use of antihypertensive medications and 24-hour sleep in nursing homes: results from the randomized controlled COSMOS trial. BMC Geriatr 2021; 21:430. [PMID: 34275457 PMCID: PMC8286557 DOI: 10.1186/s12877-021-02317-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2020] [Accepted: 06/06/2021] [Indexed: 11/21/2022] Open
Abstract
BACKGROUND Antihypertensive medication use and sleep problems are highly prevalent in nursing home patients. While it is hypothesized that blood pressure and antihypertensive medication use can affect sleep, this has not been investigated in depth in this population. Alongside a multicomponent intervention including a systematic medication review, we aimed to investigate the longitudinal association between antihypertensive medication use, blood pressure and day- and night-time sleep over 4 months. METHODS This study was based on secondary analyses from the multicomponent cluster randomized controlled COSMOS trial, in which the acronym denotes the intervention: COmmuncation, Systematic pain assessment and treatment, Medication review, Organization of activities and Safety. We included baseline and 4-month follow-up data from a subgroup of nursing home patients who wore actigraphs (n = 107). The subgroup had different levels of blood pressure, from low (< 120) to high (≥ 141). Assessments included blood pressure, antihypertensive medication use, and sleep parameters as assessed by actigraphy. RESULTS We found a significant reduction in total sleep time at month four in the intervention group compared to the control group. When analysing the control group alone, we found a significant association between antihypertensive medication use and increased daytime sleep. We also found negative associations between blood pressure, antihypertensive medication use and sleep onset latency in the control group. CONCLUSIONS Our results suggest a correlation between excessive daytime sleep and antihypertensive medication use. These findings should be followed up with further research, and with clinical caution, as antihypertensive medications are frequently used in nursing homes, and sleep problems may be especially detrimental for this population. TRIAL REGISTRATION The trial is registered at clinicaltrials.gov ( NCT02238652 ).
Collapse
Affiliation(s)
- Elisabeth Flo-Groeneboom
- Centre for Elderly and Nursing Home Medicine, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
- Department of Clinical Psychology, University of Bergen, Postboks 7807, 5020, Bergen, Norway.
| | - Tony Elvegaard
- Centre for Elderly and Nursing Home Medicine, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway
| | - Christine Gulla
- Centre for Elderly and Nursing Home Medicine, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway
- National Centre for Emergency Primary Health Care, NORCE Norwegian Research Centre, Bergen, Norway
| | - Bettina S Husebo
- Centre for Elderly and Nursing Home Medicine, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway
- Municipality of Bergen, Bergen, Norway
| |
Collapse
|
5
|
Multiple antihypertensive use and risk of mortality in residents of aged care services: a prospective cohort study. Aging Clin Exp Res 2020; 32:1541-1549. [PMID: 31473981 DOI: 10.1007/s40520-019-01336-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2019] [Accepted: 08/21/2019] [Indexed: 12/22/2022]
Abstract
AIMS The objective of this study is to investigate the association between multiple antihypertensive use and mortality in residents with diagnosed hypertension, and whether dementia and frailty modify this association. METHODS This is a two-year prospective cohort study of 239 residents with diagnosed hypertension receiving antihypertensive therapy across six residential aged care services in South Australia. Data were obtained from electronic medical records, medication charts and validated assessments. The primary outcome was all-cause mortality and the secondary outcome was cardiovascular-related hospitalizations. Inverse probability weighted Cox models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause mortality. Covariates included age, sex, dementia severity, frailty status, Charlson's comorbidity index and cardiovascular comorbidities. RESULTS The study sample (mean age of 88.1 ± 6.3 years; 79% female) included 70 (29.3%) residents using one antihypertensive and 169 (70.7%) residents using multiple antihypertensives. The crude incidence rates for death were higher in residents using multiple antihypertensives compared with residents using monotherapy (251 and 173/1000 person-years, respectively). After weighting, residents who used multiple antihypertensives had a greater risk of mortality compared with monotherapy (HR 1.40, 95%CI 1.03-1.92). After stratifying by dementia diagnosis and frailty status, the risk only remained significant in residents with diagnosed dementia (HR 1.91, 95%CI 1.20-3.04) and who were most frail (HR 2.52, 95%CI 1.13-5.64). Rate of cardiovascular-related hospitalizations did not differ among residents using multiple compared to monotherapy (rate ratio 0.73, 95%CI 0.32-1.67). CONCLUSIONS Multiple antihypertensive use is associated with an increased risk of mortality in residents with diagnosed hypertension, particularly in residents with dementia and among those who are most frail.
Collapse
|
6
|
Sanchis-Soler G, Tortosa-Martínez J, Manchado-Lopez C, Cortell-Tormo JM. The effects of stress on cardiovascular disease and Alzheimer's disease: Physical exercise as a counteract measure. INTERNATIONAL REVIEW OF NEUROBIOLOGY 2020; 152:157-193. [PMID: 32450995 DOI: 10.1016/bs.irn.2020.01.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
AD is a complicated multi-systemic neurological disorder that involves different biological pathways. Several risk factors have been identified, including chronic stress. Chronic stress produces an alteration in the activity of the hypothalamic pituitary adrenal (HPA) system, and the autonomic nervous system (ANS), which over time increase the risk of AD and also the incidence of cardiovascular disease (CVD) and risk factors, such as hypertension, obesity and type 2 diabetes, associated with cognitive impairment and AD. Considering the multi-factorial etiology of AD, understanding the complex interrelationships between different risk factors is of potential interest for designing adequate strategies for preventing, delaying the onset or slowing down the progression of this devastating disease. Thus, in this review we will explore the general mechanisms and evidence linking stress, cardiovascular disease and AD, and discuss the potential benefits of physical activity for AD by counteracting the negative effects of chronic stress, CVD and risk factors.
Collapse
|
7
|
Svahn S, Lövheim H, Isaksson U, Sandman PO, Gustafsson M. Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden. Eur J Clin Pharmacol 2020; 76:525-537. [PMID: 31915846 DOI: 10.1007/s00228-019-02778-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2019] [Accepted: 09/26/2019] [Indexed: 11/27/2022]
Abstract
PURPOSE The aim of this study was to describe changes in the pattern of cardiovascular agents used in elderly people living in nursing homes between 2007 and 2013. Further, the aim was to analyse the use of cardiovascular drugs in relation to cognitive impairment and associated factors within the same population, where prescription of loop diuretics was used as a proxy for heart failure. METHODS Two questionnaire surveys were performed including 2494 people in 2007 and 1654 people in 2013 living in nursing homes in northern Sweden. Data were collected concerning drug use, functioning in activities of daily living (ADL) and cognition, using the Multi-Dimensional Dementia Assessment Scale (MDDAS). The use of different drugs and drug classes among people at four different levels of cognitive function in 2007 and 2013 were compared. RESULTS The proportion of people prescribed ASA and diuretics was significantly lower at all four levels of cognitive function in 2013 compared to 2007. Among people prescribed loop diuretics, the use of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEI/ARBs) increased from 37.8 to 45.6%, β-blockers from 36.0 to 41.8% and warfarin from 4.4 to 11.4%. The use of warfarin, ACEI/ARBs, β-blockers and mineralocorticoid receptor antagonists (MRAs) were less common among individuals with more severe cognitive impairment. CONCLUSION The results indicate that cardiovascular drug treatment has improved between 2007 and 2013, but there is room for further improvement, especially regarding adherence to guidelines for heart failure. Increasing cognitive impairment had an effect on treatment patterns for heart failure and atrial fibrillation.
Collapse
Affiliation(s)
- Sofia Svahn
- Department of Pharmacology and Clinical Neuroscience, Umeå University, SE-901 87, Umeå, Sweden.
| | - Hugo Lövheim
- Department of Community Medicine and Rehabilitation, Geriatric Medicine, Umeå University, SE-901 87, Umeå, Sweden
| | - Ulf Isaksson
- Department of Nursing, Umeå University, SE-901 87, Umeå, Sweden.,Arctic Research Centre at Umeå University, SE-901 87, Umeå, Sweden
| | - Per-Olof Sandman
- Department of Nursing, Umeå University, SE-901 87, Umeå, Sweden.,Department of Neurobiology, Care Sciences and Society, Division of Nursing, Karolinska Institutet, SE-171 77, Stockholm, Sweden
| | - Maria Gustafsson
- Department of Pharmacology and Clinical Neuroscience, Umeå University, SE-901 87, Umeå, Sweden
| |
Collapse
|
8
|
Delgado J, Bowman K, Clare L. Potentially inappropriate prescribing in dementia: a state-of-the-art review since 2007. BMJ Open 2020; 10:e029172. [PMID: 31900263 PMCID: PMC6955517 DOI: 10.1136/bmjopen-2019-029172] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/16/2019] [Revised: 11/12/2019] [Accepted: 11/13/2019] [Indexed: 01/14/2023] Open
Abstract
OBJECTIVES Dementia frequently occurs alongside comorbidities. Coexisting conditions are often managed with multiple medications, leading to increased risk of potentially inappropriate medication and adverse drug reactions. We aimed to estimate prevalence of, and identify factors reported to be associated with, potentially inappropriate prescribing (PIP) for older individuals diagnosed with dementia. DESIGN We used a state-of-the-art review approach, selecting papers written in English and published from 2007 to January 2018. Publications were retrieved from Scopus and Web of Science databases. Inclusion criteria included a formal diagnosis of dementia, a formal classification of PIP and reported prevalence of PIP as an outcome. Random effects models were used to provide a pooled estimate of prevalence of PIP. The Appraisal tool for Cross-Sectional Studies (AXIS tool) was used to assess bias in the included studies. RESULTS The bibliographic search yielded 221 citations, with 12 studies meeting the inclusion criteria. The estimates of PIP prevalence for people living with dementia ranged from 14% to 64%. Prevalence was 31% (95% CI 9 to 52) in the community, and 42% (95% CI 30 to 55) in nursing/care homes. PIP included prescribing likely related to dementia (eg, hypnotics and sedative and cholinesterase inhibitors) and prescribing related to treatment of comorbidities (eg, cardiovascular drugs and non-steroidal anti-inflammatory medication). Higher levels of comorbidity were associated with increased risk of PIP; however, only one study investigated associations with specific comorbidities of dementia. CONCLUSION PIP remains a significant issue in healthcare management for people living with dementia. Higher levels of comorbidity are associated with increased prevalence of PIP, but the specific conditions driving this increase remain unknown. Further work is necessary to investigate PIP related to the presence of common comorbidities in patients living with dementia.
Collapse
Affiliation(s)
- Joao Delgado
- College of Medicine and Health, University of Exeter, Exeter, Devon, UK
| | - Kirsty Bowman
- College of Medicine and Health, University of Exeter, Exeter, Devon, UK
| | - Linda Clare
- College of Medicine and Health, University of Exeter, Exeter, Devon, UK
| |
Collapse
|
9
|
de Heus RA, Olde Rikkert MG, Tully PJ, Lawlor BA, Claassen JA. Blood Pressure Variability and Progression of Clinical Alzheimer Disease. Hypertension 2019; 74:1172-1180. [DOI: 10.1161/hypertensionaha.119.13664] [Citation(s) in RCA: 43] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Blood pressure variability (BPV) has been shown to have predictive value over blood pressure (BP) levels alone in stroke patients. We assessed whether BPV predicts cognitive and functional decline in Alzheimer disease, using data from a randomized trial (NILVAD [A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer’s Disease]). Patients with mild-to-moderate Alzheimer disease were included if they had ≥3 office BP measurements available to determine visit-to-visit BPV. Day-to-day BPV was assessed using home BP measurements in a subsample. The variation independent of mean was used to calculate BPV. Outcomes were change in Alzheimer’s Disease Assessment Scale–cognitive subscale-12 and Disability Assessment for Dementia after 1 and 1.5 years. A total of 460 patients aged 72.1 (SD=8.1) years, with mean BP of 134.0/75.1 (10.9/6.3) mm Hg were included. After 1 year, patients in the highest quartile of BPV had deteriorated more on Alzheimer’s Disease Assessment Scale–cognitive subscale compared with patients in the lowest quartile (systolic: β, 2.24 [95% CI, 0.11–4.38],
P
=0.040; diastolic: β, 2.54 [95% CI, 0.33–4.75]
P
=0.024). This association was still present after 1.5 years (systolic: β, 2.86 [95% CI, 0.35–5.36],
P
=0.026; diastolic: β, 3.30 [95% CI, 0.67–5.93],
P
=0.014). There was no effect of visit-to-visit BPV on Disability Assessment for Dementia. Day-to-day BPV was available for 46 patients. Significant associations were observed between day-to-day BPV and deterioration on Alzheimer’s Disease Assessment Scale–cognitive subscale (systolic:
P
=0.036) and Disability Assessment for Dementia (systolic:
P
=0.020; diastolic:
P
=0.007) after 1 year, but not after 1.5 years. All associations were adjusted for potential confounders, including intervention group. In conclusion, this post hoc analysis indicates that higher visit-to-visit and day-to-day BPV might be associated with progression of Alzheimer disease. Targeting BPV may be a future target to slow decline in patients with Alzheimer disease.
Clinical Trial Registration
URL:
https://www.clinicaltrials.gov
. Unique identifier: NCT02017340.
Collapse
Affiliation(s)
- Rianne A.A. de Heus
- From the Department of Geriatric Medicine, Radboud umc University Medical Center, Radboudumc Alzheimer Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, the Netherlands (R.A.A.d.H., M.G.M.O.R., J.A.H.R.C.)
| | - Marcel G.M. Olde Rikkert
- From the Department of Geriatric Medicine, Radboud umc University Medical Center, Radboudumc Alzheimer Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, the Netherlands (R.A.A.d.H., M.G.M.O.R., J.A.H.R.C.)
| | - Phillip J. Tully
- School of Medicine, The University of Adelaide, Australia (P.J.T.)
| | - Brian A. Lawlor
- Mercer’s Institute for Research on Ageing, St. James’s Hospital, Dublin, Ireland (B.A.L.)
- Department of Medical Gerontology, Trinity College Institute of Neuroscience, Dublin, Ireland (B.A.L.)
| | - Jurgen A.H.R. Claassen
- From the Department of Geriatric Medicine, Radboud umc University Medical Center, Radboudumc Alzheimer Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, the Netherlands (R.A.A.d.H., M.G.M.O.R., J.A.H.R.C.)
| | | |
Collapse
|
10
|
de Heus RA, Tumelaire MV, Olde Rikkert MG, Claassen JA. Diagnostic accuracy of office blood pressure compared to home blood pressure in patients with mild cognitive impairment and dementia. Eur J Cardiovasc Nurs 2019; 18:637-642. [PMID: 31262187 PMCID: PMC6764005 DOI: 10.1177/1474515119855822] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Background: Hypertension and cognitive impairment often coexist in older people. Office
blood pressure measurement is a poor indicator for diagnosing hypertension
in the general population. However, its diagnostic accuracy has not been
substantially studied in patients with cognitive impairment. Aim: The aim of this study was to determine the proportion of misdiagnosis of
hypertension in patients with mild cognitive impairment and dementia
compared to no cognitive impairment, by comparing office blood pressure
measurement with home blood pressure measurement. Methods: A cross-sectional study including consecutive patients visiting a memory
clinic between 2014 and 2017. Home blood pressure was measured for one week
according to the European guidelines. Office blood pressure was assessed
during routine clinical practice. Using guideline definitions for normal
blood pressure and hypertension, we investigated the proportion of
disagreement between office blood pressure measurement and home blood
pressure measurement. Univariable and multivariable logistic regression
compared disagreement in diagnosis between patients with dementia, mild
cognitive impairment and no cognitive impairment. Results: Of 213 patients (aged 73.4±9.0 years, 42% women) 82 had dementia, 65 had mild
cognitive impairment and 66 had no cognitive impairment. Mean office blood
pressure was 156/84±23/11 mmHg and mean home blood pressure was 139/79±16/10
mmHg. In 31% of patients, there was disagreement in hypertension diagnosis.
This proportion was higher for mild cognitive impairment (38.5%) and
dementia (35.4%) compared to no cognitive impairment (18.2%), with adjusted
odds ratios of 3.7 (95% confidence interval 1.5–9.0),
P=0.005 for mild cognitive impairment and 3.4 (1.3–8.6),
P=0.011 for dementia. Conclusions: In memory clinic patients with dementia and mild cognitive impairment, the
diagnostic accuracy of office blood pressure measurement is lower compared
to patients without cognitive impairment. To avoid the risk of making
improper treatment decisions in this vulnerable group, a diagnosis of
hypertension should be based on home blood pressure measurement, not office
blood pressure measurement.
Collapse
Affiliation(s)
- Rianne Aa de Heus
- Department of Geriatric Medicine, Radboud University Medical Center, The Netherlands.,Radboudumc Alzheimer Center, Radboud University Medical Center, The Netherlands
| | - Maxime V Tumelaire
- Department of Geriatric Medicine, Radboud University Medical Center, The Netherlands.,Radboudumc Alzheimer Center, Radboud University Medical Center, The Netherlands
| | - Marcel Gm Olde Rikkert
- Department of Geriatric Medicine, Radboud University Medical Center, The Netherlands.,Radboudumc Alzheimer Center, Radboud University Medical Center, The Netherlands
| | - Jurgen Ahr Claassen
- Department of Geriatric Medicine, Radboud University Medical Center, The Netherlands.,Radboudumc Alzheimer Center, Radboud University Medical Center, The Netherlands
| |
Collapse
|
11
|
Morley JE, Vellas B. Patient-Centered (P4) Medicine and the Older Person. J Am Med Dir Assoc 2019; 18:455-459. [PMID: 28549701 DOI: 10.1016/j.jamda.2017.04.001] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2017] [Accepted: 04/04/2017] [Indexed: 12/25/2022]
Affiliation(s)
- John E Morley
- Division of Geriatric Medicine, Saint Louis University School of Medicine, St. Louis, MO.
| | - Bruno Vellas
- Gérontopôle, CHU Toulouse University Hospital and INSERM U1027, Toulouse, France
| |
Collapse
|
12
|
de Heus RAA, Donders R, Santoso AMM, Olde Rikkert MGM, Lawlor BA, Claassen JAHR. Blood Pressure Lowering With Nilvadipine in Patients With Mild-to-Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension. J Am Heart Assoc 2019; 8:e011938. [PMID: 31088188 PMCID: PMC6585342 DOI: 10.1161/jaha.119.011938] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/28/2019] [Accepted: 04/16/2019] [Indexed: 12/23/2022]
Abstract
Background Hypertension is common among patients with Alzheimer disease. Because this group has been excluded from hypertension trials, evidence regarding safety of treatment is lacking. This secondary analysis of a randomized controlled trial assessed whether antihypertensive treatment increases the prevalence of orthostatic hypotension (OH) in patients with Alzheimer disease. Methods and Results Four hundred seventy-seven patients with mild-to-moderate Alzheimer disease were randomized to the calcium-channel blocker nilvadipine 8 mg/day or placebo for 78 weeks. Presence of OH (blood pressure drop ≥20/≥10 mm Hg after 1 minute of standing) and OH-related adverse events (dizziness, syncope, falls, and fractures) was determined at 7 follow-up visits. Mean age of the study population was 72.2±8.2 years and mean Mini-Mental State Examination score was 20.4±3.8. Baseline blood pressure was 137.8±14.0/77.0±8.6 mm Hg. Grade I hypertension was present in 53.4% (n=255). After 13 weeks, blood pressure had fallen by -7.8/-3.9 mm Hg for nilvadipine and by -0.4/-0.8 mm Hg for placebo ( P<0.001). Across the 78-week intervention period, there was no difference between groups in the proportion of patients with OH at a study visit (odds ratio [95% CI]=1.1 [0.8-1.5], P=0.62), nor in the proportion of visits where a patient met criteria for OH, corrected for number of visits (7.7±13.8% versus 7.3±11.6%). OH-related adverse events were not more often reported in the intervention group compared with placebo. Results were similar for those with baseline hypertension. Conclusions This study suggests that initiation of a low dose of antihypertensive treatment does not significantly increase the risk of OH in patients with mild-to-moderate Alzheimer disease. Clinical Trial Registration URL: https://www.clinicaltrials.gov . Unique identifier: NCT02017340.
Collapse
Affiliation(s)
- Rianne A. A. de Heus
- Department of Geriatric MedicineRadboud University Medical CenterDonders Institute for Brain Cognition and BehaviourNijmegenThe Netherlands
- Radboudumc Alzheimer CenterNijmegenThe Netherlands
| | - Rogier Donders
- Department for Health EvidenceRadboud University Medical CenterNijmegenThe Netherlands
| | - Angelina M. M. Santoso
- Department of Geriatric MedicineRadboud University Medical CenterDonders Institute for Brain Cognition and BehaviourNijmegenThe Netherlands
- Radboudumc Alzheimer CenterNijmegenThe Netherlands
| | - Marcel G. M. Olde Rikkert
- Department of Geriatric MedicineRadboud University Medical CenterDonders Institute for Brain Cognition and BehaviourNijmegenThe Netherlands
- Radboudumc Alzheimer CenterNijmegenThe Netherlands
| | - Brian A. Lawlor
- Mercer's Institute for Research on AgeingSt. James's HospitalDublinIreland
- Department of Medical GerontologyTrinity College Institute of NeuroscienceDublinIreland
| | - Jurgen A. H. R. Claassen
- Department of Geriatric MedicineRadboud University Medical CenterDonders Institute for Brain Cognition and BehaviourNijmegenThe Netherlands
- Radboudumc Alzheimer CenterNijmegenThe Netherlands
| |
Collapse
|
13
|
Affiliation(s)
- Daniel A Nation
- From the Department of Psychology and Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles.
| |
Collapse
|
14
|
de Heus RA, de Jong DL, Sanders ML, van Spijker GJ, Oudegeest-Sander MH, Hopman MT, Lawlor BA, Olde Rikkert MG, Claassen JA. Dynamic Regulation of Cerebral Blood Flow in Patients With Alzheimer Disease. Hypertension 2018; 72:139-150. [DOI: 10.1161/hypertensionaha.118.10900] [Citation(s) in RCA: 44] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2018] [Revised: 02/09/2018] [Accepted: 04/05/2018] [Indexed: 01/18/2023]
Abstract
Cerebral autoregulation and baroreflex sensitivity are key mechanisms that maintain cerebral blood flow. This study assessed whether these control mechanisms are affected in patients with dementia and mild cognitive impairment due to Alzheimer disease, as this would increase the risks of antihypertensive treatment. We studied 53 patients with dementia (73.1 years [95% confidence interval (CI), 71.4–74.8]), 37 patients with mild cognitive impairment (69.2 years [95% CI, 66.4–72.0]), and 47 controls (69.4 years [95% CI, 68.3–70.5]). Beat-to-beat blood pressure (photoplethysmography), heart rate, and cerebral blood flow velocity (transcranial Doppler) were measured during 5-minute rest (sitting) and 5 minutes of orthostatic challenges, using repeated sit-to-stand maneuvers. Cerebral autoregulation was assessed using transfer function analysis and the autoregulatory index. Baroreflex sensitivity was estimated with transfer function analysis and by calculating the heart rate response to blood pressure changes during the orthostatic challenges. Dementia patients had the lowest cerebral blood flow velocity (
P
=0.004). During rest, neither transfer function analysis nor the autoregulatory index indicated impairments in cerebral autoregulation. During the orthostatic challenges, higher autoregulatory index (
P
=0.011) and lower transfer function gain (
P
=0.017), indicating better cerebral autoregulation, were found in dementia (4.56 arb. unit [95% CI, 4.14–4.97]; 0.59 cm/s per mm Hg [95% CI, 0.51–0.66]) and mild cognitive impairment (4.59 arb. unit [95% CI, 4.04–5.13]; 0.51 cm/s per mm Hg [95% CI, 0.44–0.59]) compared with controls (3.71 arb. unit [95% CI, 3.35–4.07]; 0.67 cm/s per mm Hg [95% CI, 0.59–0.74]). Baroreflex sensitivity measures did not differ between groups. In conclusion, the key mechanisms to control blood pressure and cerebral blood flow are not reduced in 2 stages of Alzheimer disease compared with controls, both in rest and during orthostatic changes that reflect daily life challenges.
Collapse
Affiliation(s)
- Rianne A.A. de Heus
- From the Department of Geriatric Medicine, Radboud Alzheimer Centre (R.A.A.d.H., D.L.K.d.J., M.L.S., G.J.v.S., M.H.O.-S., M.G.M.O.R., J.A.H.R.C.)
- Donders Institute for Brain Cognition and Behaviour, Nijmegen, The Netherlands (R.A.A.d.H., D.L.K.d.J., M.L.S., G.J.v.S., M.H.O.-S., M.G.M.O.R., J.A.H.R.C.)
| | - Daan L.K. de Jong
- From the Department of Geriatric Medicine, Radboud Alzheimer Centre (R.A.A.d.H., D.L.K.d.J., M.L.S., G.J.v.S., M.H.O.-S., M.G.M.O.R., J.A.H.R.C.)
- Donders Institute for Brain Cognition and Behaviour, Nijmegen, The Netherlands (R.A.A.d.H., D.L.K.d.J., M.L.S., G.J.v.S., M.H.O.-S., M.G.M.O.R., J.A.H.R.C.)
| | - Marit L. Sanders
- From the Department of Geriatric Medicine, Radboud Alzheimer Centre (R.A.A.d.H., D.L.K.d.J., M.L.S., G.J.v.S., M.H.O.-S., M.G.M.O.R., J.A.H.R.C.)
- Donders Institute for Brain Cognition and Behaviour, Nijmegen, The Netherlands (R.A.A.d.H., D.L.K.d.J., M.L.S., G.J.v.S., M.H.O.-S., M.G.M.O.R., J.A.H.R.C.)
| | - Gerrita J. van Spijker
- From the Department of Geriatric Medicine, Radboud Alzheimer Centre (R.A.A.d.H., D.L.K.d.J., M.L.S., G.J.v.S., M.H.O.-S., M.G.M.O.R., J.A.H.R.C.)
- Donders Institute for Brain Cognition and Behaviour, Nijmegen, The Netherlands (R.A.A.d.H., D.L.K.d.J., M.L.S., G.J.v.S., M.H.O.-S., M.G.M.O.R., J.A.H.R.C.)
| | - Madelijn H. Oudegeest-Sander
- From the Department of Geriatric Medicine, Radboud Alzheimer Centre (R.A.A.d.H., D.L.K.d.J., M.L.S., G.J.v.S., M.H.O.-S., M.G.M.O.R., J.A.H.R.C.)
- Department of Physiology (M.H.O.-S., M.T.H.), Radboud University Medical Center, Nijmegen, The Netherlands
- Donders Institute for Brain Cognition and Behaviour, Nijmegen, The Netherlands (R.A.A.d.H., D.L.K.d.J., M.L.S., G.J.v.S., M.H.O.-S., M.G.M.O.R., J.A.H.R.C.)
| | - Maria T. Hopman
- Department of Physiology (M.H.O.-S., M.T.H.), Radboud University Medical Center, Nijmegen, The Netherlands
| | - Brian A. Lawlor
- Mercer's Institute for Research on Ageing, St. James's Hospital and Global Brain Health Institute, Trinity College Dublin, Ireland (B.A.L.)
| | - Marcel G.M. Olde Rikkert
- From the Department of Geriatric Medicine, Radboud Alzheimer Centre (R.A.A.d.H., D.L.K.d.J., M.L.S., G.J.v.S., M.H.O.-S., M.G.M.O.R., J.A.H.R.C.)
- Donders Institute for Brain Cognition and Behaviour, Nijmegen, The Netherlands (R.A.A.d.H., D.L.K.d.J., M.L.S., G.J.v.S., M.H.O.-S., M.G.M.O.R., J.A.H.R.C.)
| | - Jurgen A.H.R. Claassen
- From the Department of Geriatric Medicine, Radboud Alzheimer Centre (R.A.A.d.H., D.L.K.d.J., M.L.S., G.J.v.S., M.H.O.-S., M.G.M.O.R., J.A.H.R.C.)
- Donders Institute for Brain Cognition and Behaviour, Nijmegen, The Netherlands (R.A.A.d.H., D.L.K.d.J., M.L.S., G.J.v.S., M.H.O.-S., M.G.M.O.R., J.A.H.R.C.)
| |
Collapse
|
15
|
van der Wardt V, Burton JK, Conroy S, Welsh T, Logan P, Taggar J, Tanajewski L, Gladman J. Withdrawal of antihypertensive therapy in people with dementia: feasibility study. Pilot Feasibility Stud 2018; 4:29. [PMID: 29340166 PMCID: PMC5759798 DOI: 10.1186/s40814-017-0221-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2016] [Accepted: 12/15/2017] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND This study explored the feasibility of a randomised controlled withdrawal trial of antihypertensive medication in normotensive people with dementia. Feasibility aspects included response, recruitment, exclusion and drop-out rates, suitability of outcome measures, acceptability of study procedures and an indicative economic evaluation for a randomised controlled trial. METHODS A cohort study attempting the withdrawal of antihypertensive drugs where appropriate and a feasibility study of home-based blood pressure monitoring, in people with dementia treated for hypertension, was undertaken. Interviews with participants and carers and an indicative economic evaluation were also undertaken. RESULTS Three hundred and sixty-two primary care practices in the East Midlands were contacted of which only 41 (11% (95%CI 8-15%)) agreed to support the study. These 41 practices posted 940 letters to potential participants. Thirty participants were enrolled in the cohort study of whom 9 were eligible for the antihypertensive withdrawal programme, 20 participated in a home blood pressure monitoring sub-group analysis and 12 took part in an interview study. Twenty-two of those enrolled in the cohort study were followed up at 6 months. The withdrawal programme was acceptable to participants and general practitioners (GPs). The study procedures including assessments and home blood pressure monitoring were acceptable to the participants and their carers. The economic evaluation was not possible. CONCLUSION A withdrawal trial of antihypertensive medication in normotensive people with dementia may not be feasible in the UK because of low recruitment rates.
Collapse
Affiliation(s)
- Veronika van der Wardt
- Division of Rehabilitation and Ageing, School of Medicine, University of Nottingham, Nottingham, NG7 2UH UK
| | - Jennifer K. Burton
- Centre for Cognitive Ageing and Cognitive Epidemiology & The Alzheimer Scotland Dementia Research Centre, Royal Infirmary of Edinburgh, Edinburgh, EH16 4SA UK
| | - Simon Conroy
- Department of Health Sciences, University of Leicester, Leicester, LE1 6TP UK
| | - Tomas Welsh
- Research Institute for the Care of Older People, Combe Parke, Bath, BA1 3NG UK
| | - Pip Logan
- Division of Rehabilitation and Ageing, School of Medicine, University of Nottingham, Nottingham, NG7 2UH UK
| | - Jaspal Taggar
- Division of Primary Care School of Medicine, University of Nottingham, Nottingham, NG7 2UH UK
| | - Lukasz Tanajewski
- Department of Economics, Kozminski University, Warsaw, Poland
- Division of Pharmacy Practice and Policy, School of Pharmacy, University of Nottingham, Nottingham, NG7 2RD UK
| | - John Gladman
- Division of Rehabilitation and Ageing, School of Medicine, University of Nottingham, Nottingham, NG7 2UH UK
| |
Collapse
|
16
|
Georgakis MK, Protogerou AD, Kalogirou EI, Kontogeorgi E, Pagonari I, Sarigianni F, Papageorgiou SG, Kapaki E, Papageorgiou C, Tousoulis D, Petridou ET. Blood Pressure and All-Cause Mortality by Level of Cognitive Function in the Elderly: Results From a Population-Based Study in Rural Greece. J Clin Hypertens (Greenwich) 2017; 19:161-169. [PMID: 27436635 PMCID: PMC8030920 DOI: 10.1111/jch.12880] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2016] [Revised: 06/02/2016] [Accepted: 06/09/2016] [Indexed: 12/24/2022]
Abstract
This study aimed to investigate whether the effect of blood pressure (BP) on mortality differs by levels of cognitive function. The associations of brachial systolic BP, diastolic BP, mean arterial pressure (MAP), and pulse pressure with all-cause mortality were prospectively explored (follow-up 7.0±2.2 years) in 660 community-dwelling individuals (≥60 years) using adjusted Cox models, stratified by cognitive impairment (Mini-Mental State Examination [MMSE] <24). No association between brachial BP variables and mortality was shown for the total sample in quartiles analysis; however, MAP in the highest quartile, compared with the second, was associated with mortality (hazard ratio, 1.85; 95% confidence intervals, 1.09-3.12) among cognitively impaired individuals. The fractional-polynomials approach for BP confirmed this finding and further showed, solely in the MMSE <24 subcohort, U-shaped trends of MAP and systolic BP, with increased mortality risk in extremely low or high values; no such pattern was evident for patients with MMSE ≥24. Elderly individuals with cognitive impairment might be more susceptible to the detrimental effects of low and elevated MAP and systolic BP.
Collapse
Affiliation(s)
- Marios K. Georgakis
- Department of Hygiene, Epidemiology and Medical StatisticsSchool of MedicineNational and Kapodistrian University of AthensAthensGreece
| | - Athanasios D. Protogerou
- Cardiovascular Prevention and Research UnitDepartment of PathophysiologySchool of MedicineNational and Kapodistrian University of AthensAthensGreece
| | - Eleni I. Kalogirou
- Department of Hygiene, Epidemiology and Medical StatisticsSchool of MedicineNational and Kapodistrian University of AthensAthensGreece
| | - Evangelia Kontogeorgi
- Department of Hygiene, Epidemiology and Medical StatisticsSchool of MedicineNational and Kapodistrian University of AthensAthensGreece
| | - Ioanna Pagonari
- Health Centre of VelestinoAhillopouleio General Hospital of VolosVelestinoVolosGreece
| | - Fani Sarigianni
- Health Centre of VelestinoAhillopouleio General Hospital of VolosVelestinoVolosGreece
| | - Sokratis G. Papageorgiou
- Second Department of NeurologyAttikon University General HospitalSchool of MedicineNational and Kapodistrian University of AthensChaidariAthensGreece
| | - Elisabeth Kapaki
- First Department of NeurologyEginition HospitalSchool of MedicineNational and Kapodistrian University of AthensAthensGreece
| | - Charalampos Papageorgiou
- First Department of PsychiatryEginition HospitalSchool of MedicineNational and Kapodistrian University of AthensAthensGreece
| | - Dimitrios Tousoulis
- First Department of CardiologyHippokrateion HospitalSchool of MedicineNational and Kapodistrian University of AthensAthensGreece
| | - Eleni Th. Petridou
- Department of Hygiene, Epidemiology and Medical StatisticsSchool of MedicineNational and Kapodistrian University of AthensAthensGreece
- First Department of CardiologyHippokrateion HospitalSchool of MedicineNational and Kapodistrian University of AthensAthensGreece
| |
Collapse
|
17
|
The association between SBP and mortality risk differs with level of cognitive function in very old individuals. J Hypertens 2016; 34:745-52. [PMID: 26938812 PMCID: PMC4947532 DOI: 10.1097/hjh.0000000000000831] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Objective: Cognitive impairment and dementia are highly prevalent in very old populations. Cardiovascular disease is a common cause of death in people with dementia. This study investigated whether the association of blood pressure (BP) with mortality differed with respect to mini-mental state examination (MMSE) score in a representative sample of very old individuals. Methods: The sample consisted of 1115 participants aged 85, 90, and at least 95 years from the Umeå85+/GErontological Regional DAtabase cohort study. The main outcome was all-cause mortality within 2 years according to BP and MMSE score, using Cox proportional-hazard regression models adjusted for sociodemographic and clinical characteristics associated with death. Results: Mean age, MMSE score, and SBP and DBP were 89.4 ± 4.6 years, 21.1 ± 7.6, 146.1 ± 23.4 mmHg, and 74.1 ± 11.7 mmHg, respectively. Within 2 years, 293 (26%) participants died. BP was not associated independently with mortality risk, except among participants with MMSE scores of 0–10 among whom mortality risk was increased in association with SBP at least 165 mmHg and 125 mmHg or less, compared with 126–139 mmHg (adjusted hazard ratio 4.54, 95% confidence interval = 1.52–13.60 and hazard ratio 2.23, 95% confidence interval = 1.12–4.45, respectively). In age and sex-adjusted analyses, SBP 125 mmHg or less was associated with increased mortality risk in participants with MMSE scores at least 18. Conclusion: In people aged at least 85 years, the association of SBP with mortality appears to differ with respect to MMSE score. Very old individuals with very severe cognitive impairment and low or high BP may have increased mortality risk.
Collapse
|
18
|
Tan EC, Bell JS, Lu CY, Toh S. National Trends in Outpatient Antihypertensive Prescribing in People with Dementia in the United States. J Alzheimers Dis 2016; 54:1425-1435. [DOI: 10.3233/jad-160470] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- Edwin C.K. Tan
- Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Australia
- Aging Research Center, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden
| | - J. Simon Bell
- Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Australia
- Sansom Institute, University of South Australia, Adelaide, Australia
| | - Christine Y. Lu
- Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA
| | - Sengwee Toh
- Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA
| |
Collapse
|
19
|
Benetos A, Bulpitt CJ, Petrovic M, Ungar A, Agabiti Rosei E, Cherubini A, Redon J, Grodzicki T, Dominiczak A, Strandberg T, Mancia G. An Expert Opinion From the European Society of Hypertension–European Union Geriatric Medicine Society Working Group on the Management of Hypertension in Very Old, Frail Subjects. Hypertension 2016; 67:820-5. [DOI: 10.1161/hypertensionaha.115.07020] [Citation(s) in RCA: 128] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
- Athanase Benetos
- From the Department of Geriatrics and FHU CARTAGE, CHU de Nancy and INSERM 1116, Université de Lorraine, Nancy, France (A.B.); Department of Medicine Imperial College, London, United Kingdom (C.J.B.); Department of Geriatrics, Ghent University Hospital, and Ghent University, Ghent, Belgium (M.P.); Geriatric Cardiology and Medicine, University of Florence and Azienda Ospedaliero Universitaria Careggi, Firenze, Italy (A.U.); Clinica Medica, Department of Clinical and Experimental Sciences, University
| | - Christopher J. Bulpitt
- From the Department of Geriatrics and FHU CARTAGE, CHU de Nancy and INSERM 1116, Université de Lorraine, Nancy, France (A.B.); Department of Medicine Imperial College, London, United Kingdom (C.J.B.); Department of Geriatrics, Ghent University Hospital, and Ghent University, Ghent, Belgium (M.P.); Geriatric Cardiology and Medicine, University of Florence and Azienda Ospedaliero Universitaria Careggi, Firenze, Italy (A.U.); Clinica Medica, Department of Clinical and Experimental Sciences, University
| | - Mirko Petrovic
- From the Department of Geriatrics and FHU CARTAGE, CHU de Nancy and INSERM 1116, Université de Lorraine, Nancy, France (A.B.); Department of Medicine Imperial College, London, United Kingdom (C.J.B.); Department of Geriatrics, Ghent University Hospital, and Ghent University, Ghent, Belgium (M.P.); Geriatric Cardiology and Medicine, University of Florence and Azienda Ospedaliero Universitaria Careggi, Firenze, Italy (A.U.); Clinica Medica, Department of Clinical and Experimental Sciences, University
| | - Andrea Ungar
- From the Department of Geriatrics and FHU CARTAGE, CHU de Nancy and INSERM 1116, Université de Lorraine, Nancy, France (A.B.); Department of Medicine Imperial College, London, United Kingdom (C.J.B.); Department of Geriatrics, Ghent University Hospital, and Ghent University, Ghent, Belgium (M.P.); Geriatric Cardiology and Medicine, University of Florence and Azienda Ospedaliero Universitaria Careggi, Firenze, Italy (A.U.); Clinica Medica, Department of Clinical and Experimental Sciences, University
| | - Enrico Agabiti Rosei
- From the Department of Geriatrics and FHU CARTAGE, CHU de Nancy and INSERM 1116, Université de Lorraine, Nancy, France (A.B.); Department of Medicine Imperial College, London, United Kingdom (C.J.B.); Department of Geriatrics, Ghent University Hospital, and Ghent University, Ghent, Belgium (M.P.); Geriatric Cardiology and Medicine, University of Florence and Azienda Ospedaliero Universitaria Careggi, Firenze, Italy (A.U.); Clinica Medica, Department of Clinical and Experimental Sciences, University
| | - Antonio Cherubini
- From the Department of Geriatrics and FHU CARTAGE, CHU de Nancy and INSERM 1116, Université de Lorraine, Nancy, France (A.B.); Department of Medicine Imperial College, London, United Kingdom (C.J.B.); Department of Geriatrics, Ghent University Hospital, and Ghent University, Ghent, Belgium (M.P.); Geriatric Cardiology and Medicine, University of Florence and Azienda Ospedaliero Universitaria Careggi, Firenze, Italy (A.U.); Clinica Medica, Department of Clinical and Experimental Sciences, University
| | - Josep Redon
- From the Department of Geriatrics and FHU CARTAGE, CHU de Nancy and INSERM 1116, Université de Lorraine, Nancy, France (A.B.); Department of Medicine Imperial College, London, United Kingdom (C.J.B.); Department of Geriatrics, Ghent University Hospital, and Ghent University, Ghent, Belgium (M.P.); Geriatric Cardiology and Medicine, University of Florence and Azienda Ospedaliero Universitaria Careggi, Firenze, Italy (A.U.); Clinica Medica, Department of Clinical and Experimental Sciences, University
| | - Tomasz Grodzicki
- From the Department of Geriatrics and FHU CARTAGE, CHU de Nancy and INSERM 1116, Université de Lorraine, Nancy, France (A.B.); Department of Medicine Imperial College, London, United Kingdom (C.J.B.); Department of Geriatrics, Ghent University Hospital, and Ghent University, Ghent, Belgium (M.P.); Geriatric Cardiology and Medicine, University of Florence and Azienda Ospedaliero Universitaria Careggi, Firenze, Italy (A.U.); Clinica Medica, Department of Clinical and Experimental Sciences, University
| | - Anna Dominiczak
- From the Department of Geriatrics and FHU CARTAGE, CHU de Nancy and INSERM 1116, Université de Lorraine, Nancy, France (A.B.); Department of Medicine Imperial College, London, United Kingdom (C.J.B.); Department of Geriatrics, Ghent University Hospital, and Ghent University, Ghent, Belgium (M.P.); Geriatric Cardiology and Medicine, University of Florence and Azienda Ospedaliero Universitaria Careggi, Firenze, Italy (A.U.); Clinica Medica, Department of Clinical and Experimental Sciences, University
| | - Timo Strandberg
- From the Department of Geriatrics and FHU CARTAGE, CHU de Nancy and INSERM 1116, Université de Lorraine, Nancy, France (A.B.); Department of Medicine Imperial College, London, United Kingdom (C.J.B.); Department of Geriatrics, Ghent University Hospital, and Ghent University, Ghent, Belgium (M.P.); Geriatric Cardiology and Medicine, University of Florence and Azienda Ospedaliero Universitaria Careggi, Firenze, Italy (A.U.); Clinica Medica, Department of Clinical and Experimental Sciences, University
| | - Giuseppe Mancia
- From the Department of Geriatrics and FHU CARTAGE, CHU de Nancy and INSERM 1116, Université de Lorraine, Nancy, France (A.B.); Department of Medicine Imperial College, London, United Kingdom (C.J.B.); Department of Geriatrics, Ghent University Hospital, and Ghent University, Ghent, Belgium (M.P.); Geriatric Cardiology and Medicine, University of Florence and Azienda Ospedaliero Universitaria Careggi, Firenze, Italy (A.U.); Clinica Medica, Department of Clinical and Experimental Sciences, University
| |
Collapse
|
20
|
Affiliation(s)
- Y Rolland
- John E. Morley, MB, BCh, Division of Geriatric Medicine, Saint Louis University School of Medicine, 1402 S. Grand Blvd., M238, St. Louis, MO 63104,
| | | |
Collapse
|
21
|
van der Wardt V. Should guidance for the use of antihypertensive medication in older people with frailty be different? Age Ageing 2015; 44:912-3. [PMID: 26504114 DOI: 10.1093/ageing/afv147] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
|
22
|
Dharmarajan TS, Dharmarajan L. Tolerability of Antihypertensive Medications in Older Adults. Drugs Aging 2015; 32:773-96. [DOI: 10.1007/s40266-015-0296-3] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
23
|
Morley JE. White matter lesions (leukoaraiosis): a major cause of falls. J Am Med Dir Assoc 2015; 16:441-3. [PMID: 25933725 DOI: 10.1016/j.jamda.2015.03.023] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2015] [Accepted: 03/25/2015] [Indexed: 10/23/2022]
Affiliation(s)
- John E Morley
- Divisions of Geriatric Medicine and Endocrinology, Saint Louis University School of Medicine, St. Louis, MO.
| |
Collapse
|
24
|
Kaehr E, Visvanathan R, Malmstrom TK, Morley JE. Frailty in Nursing Homes: The FRAIL-NH Scale. J Am Med Dir Assoc 2015; 16:87-9. [DOI: 10.1016/j.jamda.2014.12.002] [Citation(s) in RCA: 75] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2014] [Accepted: 12/01/2014] [Indexed: 10/24/2022]
|
25
|
Morley JE. New Horizons in the Management of Alzheimer Disease. J Am Med Dir Assoc 2015; 16:1-5. [DOI: 10.1016/j.jamda.2014.10.022] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2014] [Accepted: 10/29/2014] [Indexed: 12/21/2022]
|